QGEN Stock Analysis: Buy, Sell, or Hold?
QGEN - QIAGEN N.V.
$33.29
0.59 (1.80%)
▲
5d:
-0.66%
30d:
-20.05%
90d:
-34.53%
HOLD
MODERATE Confidence
Analysis Updated: May 14, 2026 12:00 AM ET
Earnings: May 06, 2026
0d
Get Alerted When QGEN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: QGEN shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: QGEN shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$59.12
Based on 6.3% avg growth
INTRINSIC VALUE TODAY
$36.71
9.3% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 16.5x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: QGEN is currently trading at $33.29, which is considered oversold relative to its 30-day fair value range of $33.90 to $40.92. From a valuation perspective, the stock is trading at a discount (Forward PE: 12.6) compared to its historical average (16.5). Remarkably, the market is currently pricing in an annual earnings decline of 8.7% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, QGEN is in a strong downtrend. The price is currently testing key support at $32.53. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: QGEN has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $44.82 (+34.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, QGEN is in a strong downtrend. The price is currently testing key support at $32.53. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: QGEN has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $44.82 (+34.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$33.90 -
$40.92
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 34.6% below Wall St target ($44.82)
Trading Range Analysis
30-Day Trading Range
$33.90 -
$40.92
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$32.53
Resistance Level
$34.84
Current Trend
Strong Downtrend
Technical data as of
May 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
12.57
Wall Street Target
$44.82
(+34.6%)
Revenue Growth (YoY)
1.8%
Earnings Growth (YoY)
-23.8%
Profit Margin
19.2%
Valuation Discount vs History
-8.7% cheaper
PE vs Historical
12.6 vs 16.5
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-8.7%
(market-implied from PE analysis)
1-Year Target
$30.39
(-9%)
2-Year Target
$27.75
(-17%)
3-Year Target
$25.34
(-24%)
3-Yr Target (if PE normalizes)
(PE: 13→17)
$33.25
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.0, Growth: 8.5%)
$74.58
(+124%)
Base:
(SPY PE: 12.6, Growth: 8.5%)
$42.55
(+28%)
Bear:
(PE: 10.7, Growth: 8.5%)
$36.16
(+9%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (17x PE), but valuation improves significantly next year (13x PE) as earnings recover.
Trailing PE: 16.68 | Current EPS (TTM): $1.96
Bull Case
$48.59
(+46%)
Analyst growth 35.1%, PE expands to 18.4
Base Case
$44.17
(+33%)
Market implied 35.1%, PE stable at 16.7
Bear Case
$22.24
(-33%)
Severe decline -20.0%, PE contracts to 14.2
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 12.6 to 16.5
Stabilization Target:
$43.69
(+31.2%)
PE Expansion Potential:
+31.2%
Share & Embed Analysis
Last updated: May 14, 2026 8:49 PM ET
Data refreshes hourly during market hours. Next update: 9:49 PM
Data refreshes hourly during market hours. Next update: 9:49 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is QGEN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Diagnostics & Research Stocks
Top-rated stocks in Diagnostics & Research by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
TMO
Thermo Fisher Scientific… |
STRONG BUY
31 analysts |
$620 | 55 HOLD |
|
EXAS
EXACT Sciences Corporati… |
STRONG BUY
26 analysts |
$106 | 65 BUY |
|
DHR
Danaher Corporation |
STRONG BUY
26 analysts |
$250 | 58 HOLD |
|
GH
Guardant Health Inc |
STRONG BUY
24 analysts |
$130 | 59 HOLD |
|
NTRA
Natera Inc |
STRONG BUY
21 analysts |
$261 | 58 HOLD |
